Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

156.97 +2.43 (+1.57%)
Official Closing Price Updated: 7:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
62 63 Next >
Could This Move by Johnson & Johnson Equal Billions for Moderna?
An RSV vaccine could be a driver of blockbuster revenue. 
Via The Motley Fool
3 Surprisingly Underrated Stocks to Buy in April
These drugmakers could deliver greater gains than many investors expect. 
Via The Motley Fool
3 Top Dividend Stocks to Buy Now for an Income-Based Portfolio
Income-based portfolios can steady the ship when volatility spikes. Let's look at a few dividend stocks to buy right now. 
Via InvestorPlace
11 Stocks: 9 Dividend Payers 2 For Growth
Not all stocks are the same, and not all stocks serve the investor’s needs. 
Via Talk Markets
The 3 Best Stocks to Buy if You Want to Retire Early
The best stocks for early retirement strike a good balance between long-term growth and reliable security. 
Via InvestorPlace
2 Unstoppable Stocks to Buy Without Hesitation Right Now
These industry giants are going from strength to strength in a volatile market. 
Via The Motley Fool
Analyst Expectations for Johnson & Johnson's Future
 
Via Benzinga
Johnson & Johnson Unusual Options Activity
 
Via Benzinga
Better Buy: AbbVie vs. Johnson & Johnson
These pharma giants beat the bear market last year. 
Via The Motley Fool
Johnson & Johnson Pulls Plug On Large Late-Stage Study Of RSV Vaccine Candidate; GSK, Pfizer Shots Are Under FDA Review
 
Via Benzinga
J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out
The company says it's refocusing its portfolio to focus on transformational medicines. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
 
Via Benzinga
Looking At Johnson & Johnson's Recent Unusual Options Activity
 
Via Benzinga
Got $5,000? These 2 Blue Chip Stocks Are Near Multi-Year Lows
Both of these stocks also provide investors with attractive dividend yields of around 3%. 
Via The Motley Fool
Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?
Curious about the "dogs of the Dow" in 2023? Here's what's happening in the darkest corner of Wall Street's most exclusive club. 
Via The Motley Fool
Top 5 "Forever" Stocks To Buy In 2023
Would you like to know about ultra-high-quality dividend growth stocks that could be considered 
Via Talk Markets
7 Dividend Aristocrats to Buy for Consistent Income Growth
The dividend aristocrats each provide consistent income growth over the long-term that those seeking passive income can rely on. 
Via InvestorPlace
Could This Drug Candidate Be a Winner for These 2 Big Pharma Stocks?
These titans of big pharma just enrolled patients into phase 3 clinical trials for this promising blood thinner. 
Via The Motley Fool
It's a Mistake to Ignore the Growth Potential of These 3 Dividend Stocks
Coca-Cola, J&J, and IBM are still solid long-term income investments. 
Via The Motley Fool
3 Blue-Chip Stocks to Buy for Stability and Safety
While there’s no such thing as 100% safe blue-chip stocks, these three are better than most when seeking to preserve capital. 
Via InvestorPlace
Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?
Impact Biomedical, a biotechnology company focused on developing innovative treatments for a wide range of diseases and conditions and one of the key businesses in the DSS Inc. (NYSE American: DSS)... 
Via Benzinga
Study Shows 186 Banks Are On The Brink Of Failure
The Fed has done it again: raised their interest rates for the 9th time on March 22, 2023, by 25 basis points. This brings the fed fund rate to 4.75%-5%. However, this move sent mixed signals. 
Via Talk Markets
Binance Suspends Trading, European Bank Trouble, Twitter To Remove Legacy Verified Checkmarks: Today's Top Stories
Reuters 
Via Benzinga
Johnson & Johnson Loses Key Tuberculosis Drug Patent In India, Makes Way For Domestic Generic Players
 
Via Benzinga
Have $1,000? 2 Smart Stocks to Buy This Month
The market is still giving investors great opportunities to buy exceptional companies. 
Via The Motley Fool
3 Safe Dow Dividend Stocks to Buy Now
These companies combine regimented growth with income for a balanced overall value. 
Via The Motley Fool
Think the Bear Market Is Over? Here's How to Invest $5,000
The worst might be in the rearview mirror as far as the latest bear market is concerned. 
Via The Motley Fool
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? 
Via News Direct
Exposures Product Safety
2 Stocks That Should Be Better Buys After Their Spinoffs This Year
The growth prospects for these two businesses should improve as they become leaner. 
Via The Motley Fool
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
62 63 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.